FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4

January 28, 2016 - The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with HCV have no symptoms of the disease until liver damage becomes apparen

U.S. FDA approves Gilead’s hepatitis C drug for expanded use

– Label Expanded to Include Patients with Genotypes 4, 5 and 6 and Patients Co-Infected with HIV –– Use of Harvoni in Combination with Ribavirin for 12 Weeks Can be Considered for Treatment-Experienced Genotype 1 Patients with Cirrhosis –FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 12, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Harvoni® (ledipasvir/sofosbuvir) for expanded use in

Patient Input Requested for Merck Interferon-Free Combo

HepCBC is seeking individual patient input for our submission to the federal government for an INTERFERON-FREE, ONE PILL/DAY drug combo, shown to be effective for genotypes 1, 3, 4, and 6, Merck Pharmaceutical's elbasvir + grazoprevir (± ribavirin). The treatment's success (96% - 100% SVR12) has been confirmed in trials including people considered 'hard to treat' including those who had failed previous treatment (including simeprevir, boceprevir, and telap

Summer of Interferon-free Hepatitis C Drug Approvals?

2015 is stacking up to have a Summer of Interferon-Free hepatitis C drug approvals! So far we've had the following approvals for provincial Pharmacare coverage (addition to provincial "formulary"):On June 29th, Ontario covered AbbVie's Holkira Pak™ for genotype 1, on July 24th, Quebec covered both Gilead's Harvoni™ and AbbVie's Holkira Pak™ for genotype 1. And on World Hepatitis Day, July 28th British Columbia, Saskatchewan, Manitoba, and Yukon started to ...

CADTH Therapeutic Review Input NEWS!

CADTH's Therapeutic Review of Hepatitis C Genotype 1 has released all of the Patient Group Input it received, and a "Draft" Scientific Review which requests Stakeholder Input by June 17th. We urge readers to read these and make a submission to this Stakeholder Review if they can. Details... CADTH Scientific Report, DRAFT - request for Stakeholder Review by June 17th (See in particular: Discussion and Conclusions, pp 139-152):http://www.cadth.ca/media/pdf/

New COMBO hepatitis C treatment from AbbVie – new factsheet

HCV Advocate in the USA has just published an excellent fact sheet on the new hepatitis C combo from AbbVie for genotype 1. Note this treatment is still unavailable in Canada, except in an approved clinical trial. Read factsheet:http://www.hcvadvocate.org/hepatitis/factsheets_pdf/Phase_3_Genotype_1_AbbVie.pdf

Sofosbuvir and Ledipasvir, a new COMBO Hepatitis C treatment

HCV Advocate in the USA has just published an excellent fact sheet on the new hepatitis C combo from Gilead, sofosbuvir (SOVALDI) and ledipasvir for genotype 1 only.  Note ledipasvir alone, or in this or any other combination, is still unavailable in Canada, except in an approved clinical trial. Read factsheet:http://www.hcvadvocate.org/hepatitis/factsheets_pdf/Phase_3_Genotype_1_SOF-LDV.pdf

Simeprevir (GALEXOS) now covered in Quebec as well!

Simeprevir (GALEXOS) is also now covered on the Quebec formulary, according to CATIE, the Canadian AIDS Treatment Information Exchange. However, it is only available to those who have already failed conventional treatment with interferon and ribavirin. It is available only to genotype 1 patients who do not have the Q80K mutation and not co-infected with HIV. MUST MEET ALL THESE QUALIFICATIONS TO GET REIMBURSED FOR SIMEPREVIR: -- to be used in association w

AbbVie`s new all-oral, 12-week Hepatitis C treatment cure rate 96% for Genotype 1

AbbVie Inc's all-oral, 12-week hepatitis C therapy cured 96 percent of 394 Genotype 1 patients, half of whom were previous `null responders` to standard treatment of pegylated interferon-ribavirin. More information below... from Yahoo  HEREhttp://ca.news.yahoo.com/abbvie-says-96-percent-patients-oral-hepatitis-c-133448285--finance.html and from AbbVie HEREhttp://abbvie.mediaroom.com/2013-12-10-AbbVie-Demonstrates-96-percent-SVR-12-in-its-Phase-III-Study-of